The low levels of Granzyme B and TRAIL produced by steady-state pDCs increase considerably after activation, and it has been proven that TLR-activated pDCs have the ability to kill several tumor-derived cell lines, including hematological cancer cells, breast cancer cells, and melanoma cells [23,59,60]. This evidence concerns the gene GZMB and breast carcinoma.